Pomerantz Law Firm Alerts Investors of uniQure Class Action Lawsuit and Important Deadlines

Investor Alert: uniQure N.V. Class Action Lawsuit

The well-regarded Pomerantz Law Firm has announced a critical class action lawsuit against uniQure N.V. (NASDAQ: QURE), which serves as a cautionary note for investors who have incurred financial losses due to their investment in the company. As investors seek clarity, Pomerantz is encouraging those affected to come forward and join what may be a significant legal proceeding.

The class action lawsuit brings to light serious allegations against uniQure, suggesting that the company and certain officers or directors may have engaged in securities fraud or other unlawful business practices. These claims stem from uniQure's communications with the U.S. Food and Drug Administration (FDA), particularly related to its investigational gene therapy program.

Why Should Investors Act?

Investors have until April 13, 2026, to request the Court's approval to become a Lead Plaintiff in the class action. This opportunity is crucial for those who purchased or otherwise acquired uniQure securities during the designated Class Period. Potential plaintiffs are encouraged to contact Pomerantz LLP's Danielle Peyton at [email protected] or call 646-581-9980 for further information. Inquiries via email should also include the investor's mailing address, phone number, and details about the shares purchased.

Pomerantz highlighted that a pivotal event occurred on November 3, 2025, when uniQure issued a public announcement detailing feedback from the FDA regarding its product AMT-130, aimed at treating Huntington's disease (HD). The FDA's recent communication suggested a departure from earlier discussions, indicating that data from certain Phase I/II studies may not sufficiently support a Biologics License Application (BLA) submission.

This development led to a sharp decline in uniQure’s stock price, plummeting by $33.40 per share—equating to approximately 49.34%—and closing at $34.29 per share the same day. Such significant drops highlight the potential impact that regulatory decisions can have on company valuations and investor confidence.

The Role of Pomerantz LLP

Founded by Abraham L. Pomerantz, a trailblazer in the realm of class action litigation, Pomerantz LLP prides itself on its long-standing commitment to advocating for victims of securities fraud and corporate misconduct. Recognized as an authority in this field, the firm has successfully recovered millions of dollars in damages for affected investors over its 85+ years of existence.

Investors are reminded that past outcomes do not guarantee future successes, and every case must be treated on its individual merits. However, the firm’s experience in tackling complex corporate and securities litigation cannot be understated.

Conclusion

In light of the potential implications for investors involved with uniQure, the opportunity to join this class action lawsuit represents a vital step towards obtaining recovery for any financial losses. Interested investors are strongly encouraged not to delay in taking the necessary action before the upcoming deadline. As one of the premier law firms dedicated to this sector, Pomerantz LLP is here to assist those seeking to navigate the complexities associated with this lawsuit and ensure their rights are protected.

For those wishing to stay informed on updates regarding the case, further information can be accessed via Pomerantz Law’s official website.